Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

New research reveals GPR31’s role in immune response to gut infections

Researchers from Osaka University discover that the GPR31 path in ‘gut surveillance’ cells detects bacterial metabolites and triggers immune responses, opening new possibilities for drug

October 22, 2024

Atropos Health Launches Gen AI App with Direct Chat-to-Database for Health Systems

What You Should Know: Atropos Health, leader in evidence generation for healthcare, today announced the launch of the Geneva OS (Generative Evidence Acceleration Operating System)

October 5, 2023

Opinion | The Heart of Healthcare Innovation Keeps Beating

Fred Pelzman is an associate professor of medicine at Weill Cornell, and has been a practicing internist for nearly 30 years. He is medical director

May 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.